

Francesco Cavalli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/564622/publications.pdf>

Version: 2024-02-01

21
papers

561
citations

932766

10
h-index

794141

19
g-index

21
all docs

21
docs citations

21
times ranked

904
citing authors

#	ARTICLE	IF	CITATIONS
1	Optimizing drug delivery in COPD: The role of inhaler devices. <i>Respiratory Medicine</i> , 2017, 124, 6-14.	1.3	131
2	Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis. <i>Pulmonary Pharmacology and Therapeutics</i> , 2016, 40, 95-103.	1.1	112
3	Impact of LABA/LAMA combination on exercise endurance and lung hyperinflation in COPD: A pair-wise and network meta-analysis. <i>Respiratory Medicine</i> , 2017, 129, 189-198.	1.3	54
4	Iron laden macrophages in idiopathic pulmonary fibrosis: The telltale of occult alveolar hemorrhage?. <i>Pulmonary Pharmacology and Therapeutics</i> , 2014, 28, 35-40.	1.1	49
5	Advances in pulmonary drug delivery devices for the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Drug Delivery</i> , 2020, 17, 635-646.	2.4	39
6	HFE gene variants and iron-induced oxygen radical generation in idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2015, 45, 483-490.	3.1	33
7	Idiopathic Pulmonary Fibrosis (IPF) incidence and prevalence in Italy. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2014, 31, 191-7.	0.2	31
8	Nonintubated surgical biopsy of undetermined interstitial lung disease: a multicentre outcome analysis. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2019, 28, 744-750.	0.5	20
9	Treatable Mechanisms in Asthma. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 111-121.	1.6	17
10	New Avenues for Phosphodiesterase Inhibitors in Asthma. <i>Journal of Experimental Pharmacology</i> , 2021, Volume 13, 291-302.	1.5	17
11	Satisfaction with chronic obstructive pulmonary disease treatment: results from a multicenter, observational study. <i>Therapeutic Advances in Respiratory Disease</i> , 2019, 13, 175346661988812.	1.0	12
12	Impact of pulmonary vascular volume on mortality in IPF: is it time to reconsider the role of vasculature in disease pathogenesis and progression?. <i>European Respiratory Journal</i> , 2017, 49, 1602345.	3.1	11
13	An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease. <i>Biologics: Targets and Therapy</i> , 2021, Volume 15, 363-374.	3.0	10
14	Is H1-antihistamine (desloratadine 5 mg, orodispersible tablet) premedication in NSAID-associated urticaria really safe and practicable in "real life"? <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 535.	2.0	6
15	Synergy across the drugs approved for the treatment of asthma. <i>Minerva Medica</i> , 2022, 113, .	0.3	6
16	Potential Drawbacks of ICS/LABA/LAMA Triple Fixed-Dose Combination Therapy in the Treatment of Asthma: A Quantitative Synthesis of Safety Profile. <i>Journal of Asthma and Allergy</i> , 2022, Volume 15, 565-577.	1.5	6
17	Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 49, 20-26.	1.1	2
18	Biomarkers for possible early detection and progression of idiopathic pulmonary fibrosis. <i>Minerva Respiratory Medicine</i> , 2021, 60, .	0.1	2

#	ARTICLE	IF	CITATIONS
19	Muscarinic receptor antagonists and airway inflammation: A systematic review on pharmacological models. <i>Heliyon</i> , 2022, 8, e09760.	1.4	2
20	Management of patients with asthma or COPD and cardiovascular disease: risks versus benefits. , 2020, , 66-81.		1
21	CD71 ^{hi} Alveolar Macrophages in Idiopathic Pulmonary Fibrosis: A Look beyond the Borders of the Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 1444-1446.	2.5	0